C
rohn's disease (CD) is a transmural, chronic inflammatory bowel disease. The exact etiology is uncertain, but it involves interplay of genetic and environmental factors. 1, 2 Because of the chronic, progressive nature of the inflammatory process, patients with CD are at risk of complications such as bowel obstruction, perforation, intra-abdominal abscess, or fistula. The latter 3 are sometimes referred to as penetrating complications of CD. 3 Previous studies have demonstrated that certain patient factors including family history, 4 environmental factors such as smoking, 5, 6 and age at diagnosis 7 are risk factors for a more aggressive disease course including the development of complicated disease.
CT enterography (CTE) and MR enterography (MRE) are the imaging (cross-sectional imaging [CSI] ) modalities of choice for evaluating the small bowel. 8 These exams are used to diagnose CD, assess disease status, and identify complications. 3, 9 The importance of CSI, especially MRE, has been more widely recognized in recent years. Clinical symptoms, colonoscopy, and CSI are key to accurately determine the location and severity of CD [10] [11] [12] and, in certain cases, assessing response to therapy. 3 Radiological evidence of mucosal healing in small bowel CD has been associated with decreased risk of hospitalization and surgery. 13 CSI can be used to help assess mucosal healing, an objective endpoint for therapy that is gaining acceptance. 3 CD patients routinely undergo several CSI studies during their disease lifetime. Our hypothesis is that successive CSI studies followed longitudinally over time can provide valuable information to the treatment team about disease progression. This information could be used to inform clinical decision making by identifying patients destined to have a more severe disease course. Our study aims to identify CSI findings that predict the development of obstructive and penetrating complications of small bowel CD. Our results demonstrate that the CSI finding of a fixed stricture, especially when associated with upstream dilatation and radiologic evidence of inflammation, is a powerful predictor of future disease complications.
MATERIALS AND METHODS
This is a single center case-control study conducted at the University of Florida, a tertiary care medical center meeting criteria for Centers for Medicare and Medicaid Services (CMS) and Health Professional Shortage Area (HPSA) based on an underserved population. Cases were defined as patients with CD who suffered complications of bowel obstruction, perforation, intra-abdominal abscess, or enteric fistula from July 2013 to June 2015. Controls were defined as age-matched CD patients who did not have these complications within the same time period. Subjects were identified with a search of the Integrated Data Repository using Informatics for Integrating Biology and the Bedside (i2b2) 14 which is an NIH-funded National Center for Biomedical computing program available at the University of Florida. Institutional review board (IRB) approval was obtained to evaluate the electronic medical record (EMR) of patients identified in the i2b2 search (IRB201401008). The EMR was used to confirm the diagnosis of CD, the complication (for cases), and the presence of CSI before the complication. Perianal fistulizing disease was not included as a penetrating complication for the purposes of our study.
To allow for examination of radiologic predictors, we selected only the CD patients who had cross-sectional abdominal imaging available before the event. The first 50 cases and controls identified by the i2b2 search who met these criteria were included in the study. This number was determined in accordance with power analysis, which was based on the inflammatory markers and clinical variables. The sample size was calculated for power of 80% and 2 tailed alpha of 0.05. One hundred eight patients met screening criteria: 51 meeting inclusion criteria for cases and 57 for controls. EMRs were reviewed for all patients, and relevant data were collected pertaining to demographics, medical and surgical treatment history, duration of disease, family history of inflammatory bowel disease (IBD), smoking history, body mass index (BMI), extraintestinal manifestations, clinical disease activity (Harvey Bradshaw Index, [HBI] ) scores, quality of life scores (Short Intestinal Bowel Disease Questionnaire, [SIBDQ]), and laboratory results (hemoglobin, Erythrocyte Sedimentation Rate, C-Reactive Protein). The HBI and SIBDQ are collected on all patients with CD at the time of each clinic visit at our institution with results recorded in the EMR. For both cases and controls, medication history, documentation regarding the use of prednisone at the time of interest and 6 months' lifetime use, use of immunomodulators and/or biologics at the time of interest, and use of biologics for a period of at least 6 months were also collected. The extent of disease and perianal involvement was documented according to the Montreal classification 15 for CD, which uses parameters of disease location, age of onset, and disease behavior.
Of the 108 patients included, 67 (62%) were women, and 41 (38%) were men with an overall age range of 16 to 75 years. Most were white (88%), and remaining (12%) belonged to African American and other races. A similar gender and racial distribution was present in both cases and controls (Table 1) . For the cases, 21 had internal fistulae, 15 bowel obstructions, 13 abdominal abscesses, and 2 bowel perforations. The disease duration in months was similar across both cases (mean 152 6 SD 144) and controls (mean 156 6 SD 146) with P ¼ 0.83. The duration since last surgery was also similar in both cases (mean 96.4 6 SD 126.2) and controls (mean 84 6 SD 79.3) with P ¼ 0.82. Among the clinical variables, there was no difference based on age, sex, race, BMI, or family history of IBD between cases and controls ( Table 1 ). There was a greater proportion of active smokers in cases versus controls (P ¼ 0.033) but no difference for former smoking (Table 1 ; P ¼ 0.066). Cases had a higher incidence of surgery for IBD as compared to controls (Table 4 ; P ¼ 0.0014) and history of multiple previous surgeries for IBD (P ¼ 0.0007). We found no difference between cases and controls in comparing medication history of use of prednisone (P ¼ 0.82), a lifetime history of ever using prednisone for a period of 6 months (P ¼ 0.84), or treatment with either an immunomodulator (P ¼ 0.54) or biologic (P ¼ 0.55). The HBI was higher in cases compared with controls (8.8 6 7.87 versus 5.9 6 5.43, P ¼ 0.02). The cases had higher levels of the inflammatory markers ESR and CRP, and controls had a higher mean hemoglobin than cases. Disease duration since last surgery did not differ between cases and controls. On the multivariate logistic regression model of the demographic, clinical, and laboratory variables, ESR (P , 0.0001) remained significant.
Timeline of Data Capture
The "event date" was defined as the date in the EMR when the first indication of a complication was noted. The onset of internal fistula was also defined as the date when it was initially documented in EMR or imaging results. For cases, the "event date" was used as a reference point for collecting nonradiological data. Data were collected 6 (63) months before the date of the complicating event in individual cases.
For controls, there was no complicating event; hence, a different reference point was needed. We used September 2014 as the reference point for this purpose, which was determined to be the median time of all events in the cases. Data were collected 6 (63) months before this time (corresponding to the period between January and June, 2014) in a similar fashion to the cases.
The "time of interest" was defined as the time point at which clinical data were collected in cases and controls. In cases, this was 3 to 9 months before a complicating event (6 6 3 months of event); and in controls this was January to June, 2014 (6 6 3 months before reference point of September 2014).
Radiology Data Collection
Two gastrointestinal radiologists independently examined the previous imaging scans of all patients and scored small bowel lesions according to a published scoring system 13 ( Table 2) that has been previously used in similar studies. There were 43 lesions scored for cases and 37 for controls. Three patients each in cases and controls had more than one small bowel lesion that was scored on a single scan. Radiologists remained blinded to the outcomes of the patients. Both interpreting radiologists are board certified in diagnostic radiology and completed fellowships in abdominal imaging. One radiologist has 12 years of interpretive experience in an academic practice, and the other radiologist has 2 years of interpretive experience in an academic practice. A standardized score sheet captured the length of the lesion (centimeter), enhancement, thickness of the small bowel lesion, presence of perienteric fluid, comb sign (hypervascularity adjacent to bowel), fixed stricture, minimal lumen in mm, and progression of disease as compared with previous scans. Hypervascularity adjacent to loops of bowel can often appear as prongs of a comb because of the pattern of distribution of the vasa recta, and hence also referred to as comb sign. 16 Thickness was scored as mild (3 $ 5 mm), moderate (5-9 mm), or severe ($10 mm). Any global evidence of active inflammation was assigned a score of 1. A fixed stricture was defined as a fixed point of stenosis lasting for the entire duration of the imaging study associated with abnormal bowel wall thickening. This was to differentiate it from the transient luminal narrowing resulting from peristalsis. For MRE, stenosis was associated with a T2 signal abnormality (either hyperintense or hypointense) and for CTE, stenosis had changes in mucosal enhancement. We further stratified strictures as mild (no upstream bowel dilation), moderate (upstream dilation between 2 and 4 cm in caliber), and severe (upstream ductal dilation exceeding 4 cm in caliber). The smallest diameter was recorded as the minimal lumen dimension (Figs. 1-4 for radiological features of CD on CSI).
The CSI of choice for imaging CD at our center is MRE. Therefore, most imaging exams reviewed in both cases and controls used a standard MRE protocol. 17 CTE exams, and routine CT and MRI abdomen and pelvis, using their respective protocols commonly used in evaluation of the abdomen, were evaluated where available. The number of available previous CSI exams (in the past 10 years) separated by a time duration of at least 1 month was also recorded. Multiple scans conducted on a patient within the same 30-day period were counted as one for this purpose of this study, given that they would likely not provide additional information for our predictor parameters. MREs were performed on a 1.5 T GE Signa Gemsow (Harvey, IL), or on a 1.5 T Siemens Avanto or 3 T Siemens Verio (Erlangen, Germany). Axial and coronal T2 SS/ HASTE with and without fat saturation sequences were performed after ingestion of 4 bottles of Volumen and intravenous injection of 1 mg glucagon. Axial and coronal T1 3D FSPGR LAVA/VIBE sequences were obtained before and after intravenous injection of an extracellular gadolinium-based contrast agent. Axial diffusionweighted images and coronal cine 2D SSFP FIESTA/TrueFISP sequences were also performed. CTEs were performed on a 64 slice scanner after ingestion of 4 bottles of Volumen and intravenous injection of 150 mL Omnipaque 350 at a rate of 3 mL/sec. Axial 2 mm thin sections were reconstructed with 3 mm thick coronal reformatted images. Of the 31 controls who had an MRE, all 31 were scanned on a 1.5T GE GEMSOW. Of the 27 cases who had an MRE, 24 were scanned on a 1.5T GE GEMSOW, and 3 were scanned on a 1.5T Siemens Avanto. Of the 3 controls who had a CTE, all 3 were scanned on a 64 slice Toshiba CT scanner. Of the 10 cases who had a CTE or CT abdomen and pelvis, all 10 were scanned on a 64 slice Toshiba CT scanner.
A kappa score (for interobserver variability) was calculated from the first 10 scores and was 0.88. Any score discordance of 2 points or greater was resolved by consensus between the radiologists. The investigators averaged score discordances of 1 point (9.8% of observations).
Statistical Analysis
Data were analyzed using the statistical software SAS 9.4 (Copyright© 2013, SAS Institute Inc., Cary, NC). A student's t test was used for assessing the association of each of the continuous variables with the primary outcome of CD complications, and Fisher's exact test was used to test the dependence between each of the categorical variables with the primary outcome for the initial analysis. The variables in which ascending scores corresponded with increasing intensity or severity of the variable were considered as continuous for the purposes of this analysis. Results are presented in Tables 1, 3 , and 4, and all the P values ,0.05 are highlighted in italics. The results for HBI, CRP, and history of multiple surgeries were further confirmed by the Wilcoxon rank sum test because of the concern of potential outliers in these variables. Similar conclusions were observed (results not shown). Multivariate logistic regression was performed with both the sets of clinical and radiologic variables as covariates, and a backward selection procedure was used to build the final model. Specifically, for all samples, we started a model with all demographic, clinical, and laboratory variables. The second model started with all the radiology variables, because this set only included data of patients with scored small bowel lesions.
RESULTS
In the 51 cases, the types of scans reviewed were as follows: 31 MRE, 5 CTE, 2 MR scans of the abdomen, and 13 CT scans of the abdomen and pelvis. In the 57 controls, the types of scans were 48 MREs, 6 CTEs, 1 MR of the abdomen, and 2 CT scans of the abdomen. Over the past 10 years, the cases had an average of 2.2 (6SD 1.34, range 1-5) CSI scans separated by time intervals of more than a month, whereas the controls had 1.8 (6SD 1.6, range 1-11). The average duration from reviewed scan to complicating event in cases was 15.4 months (6SD 17.11). In controls, the duration from reviewed scan to reference point for data collection (September 2014) was also fairly similar to cases at 12.3 months (6SD 3.4). On average, the scans spanned a time period of 15 months in cases and 27 months in controls. Table 3 shows the radiologic data obtained from the preevent scans. The length of the lesions did not differ between the 2 groups. There was no difference in the findings that reflects tissue inflammation including bowel wall enhancement, comb sign, or the radiologist's impression of active inflammation. There was 1 case of complex fistula in the cases where an enteroenteric and an enterovesical fistula were both present. There was no difference in the thickness of the involved small bowel segment between cases and controls. Among the imaging variables, there was a statistically significant difference in the presence of a stricture (P ¼ 0.01) between cases (1.39 6 SD 0.95) and controls (0.88 6 SD 0.78). The odds ratio (OR) of having prestenotic dilation (scores of 2 and 3) with a bowel stricture on radiology were calculated separately. Prestenotic dilation (scores of 2 and 3) was present more commonly in the cases (33%) as compared to the controls (12%) with OR 3.43 (95% CI 1.05-10.64, P ¼ 0.038). In addition, the OR for having The presence of a stricture remained statistically significant on the multivariate logistic regression model for radiological variables (P ¼ 0.017). The minimal lumen diameter was not statistically different between the groups (P ¼ 0.12). In the scans before the time of interest, there was no difference in the presence of perienteric fluid or any internal fistulae. The statistical analysis was also performed in a similar manner for the individual scores of both radiologists, and the results remained consistent with stricture being the statistically significant variable on both t test and logistic regression. Minimal luminal diameter achieved significance on one reader's scores and not the other. The OR between cases and controls for stricture with prestenotic dilation alone and in combination with inflammation also reflected similar findings as above.
DISCUSSION
Our modern understanding of CD pathogenesis suggests that the disease evolves over time and is influenced by genetics, immune mechanisms, and the environment, especially the microbial environment, of the gut lumen. Patients at any one point in time can be categorized as having either an inflammatory, fibrostenotic, or fistulizing phenotype, but that phenotype is not static. Thanks to the pivotal work of Cosnes and others, we know that CD evolves over time from an inflammatory disease to a fibrotic and fistulizing disease. [18] [19] [20] Early in the disease course, patients typically have symptoms resulting from the gut and systemic inflammation. As the disease progresses, symptoms arise from complications including fistula, stricture, or abscess formation. Our new generation of therapies have markedly reduced inflammatory symptoms; however, data demonstrating their ability to decrease penetrating complications are less secure. Armed with this knowledge, the aim of this study was to use the commonly performed CSI studies to look at the disease in a new manner. In addition to answering specific questions at a single point in time, we investigated the possibility of using scans to predict impending complications. We found that the presence of a fixed stricture predicts future penetrating and obstructive complications of CD. Indeed, a stricture with upstream dilatation was 3.4 times more likely to develop a complication in the next 2 years. When present in the setting of hypervascularity and/or evidence of active inflammation, the risk increased further to 15-fold. This information should alert the clinician to risk and could prompt a change in medical therapy, monitoring, or change in the risk/benefit analysis that precedes decisions regarding surgery. Clearly, a discussion with the patient as to the potential implications of this finding is indicated. Our findings are supported by the recent work of Gibson et al, 3 who investigated the usefulness of MRE findings as a predictor of failure of anti-TNF therapy. Their study demonstrates that patients with small bowel stricture are at risk of treatment failure and early surgical intervention. In addition, Deepak et al 13 recently demonstrated that evidence of mucosal healing and response to medical management on CSI was linked to decreased risk of hospitalization, surgery, and corticosteroid usage among small bowel CD patients.
Interestingly, CSI findings of inflammation, in the absence of a stricture, did not predict complications. Specifically, there was no statistical significance of bowel wall enhancement, hypervascularity (comb sign), or radiologists' global impression of inflammation between cases and controls. However, there was a significant risk when hypervascularity and inflammation were noted in combination with a stricture having prestenotic dilation. Although we know that tissue inflammation is important to patient symptoms, disease characteristics such as the relapsing nature of inflammation and the dynamic changes in response to therapy could affect these CSI findings and alter their ability to predict complications.
Examining clinical parameters, we found that patients who were active smokers, and had a history of bowel surgery for IBD, elevated inflammatory markers, low hemoglobin, and increased disease activity based on the HBI had an increased risk of disease complications. From among these, the results for ESR as a predictor of complications remained significant on multivariate logistic regression. From a broader perspective, all of the above are the hallmark of a progressive and poorly controlled disease that may not be responsive to medical therapy. The correlation of smoking with complications of IBD adds to previous evidence of its detrimental effects 5, 6, 21 and support our educational efforts aimed at smoking cessation, as this effect was mitigated in former smokers. These clinical risk factors have been noted in previous retrospective studies as predictors of aggressive or complicated disease. 22 Finally, we were unable to observe significant differences based on types of medical therapy, including prednisone, immunomodulators, and biologic agents.
A fixed stricture emerged as the radiographic finding most predictive of a future obstructive or penetrating complication. The definition of a bowel stricture varies across disciplines. 23 Gastroenterologists often define an ileal stricture as a bowel segment that is too narrow to traverse with a colonoscope. Surgeons refer to a stricture as an obstructive, fibrotic bowel narrowing. Radiologists are most comfortable identifying a stricture as bowel narrowing associated with upstream dilatation. For the purposes of our study, we defined a stricture as a fixed point of stenosis associated with abnormal bowel wall thickening and, in an MRI exam, T2 signal abnormality. In identifying significant strictures, it is important that the finding be "fixed" and not affected majorly by peristalsis or underdistention. The longer examination time and multiple sequences of MR allow for greater confidence in diagnosing strictures 23, 24 as compared to CT. The findings are more easily characterized with use of modern neutral oral contrast agents such as Volumen (E-Z-EM, Inc., New York, NY) as used in CTE and MRE protocols. We further stratified strictures based on the amount of upstream dilatation. Our study reaffirms the opinion that upstream dilatation has important prognostic significance when describing a stricture.
Modern imaging techniques have not reached the point where we can distinguish inflammatory from fibrotic strictures with confidence. The difference between a predominately inflammatory stricture and a fibrotic one has important clinical implications. It impacts our decisions about medical therapy and the timing of surgical therapy. Using CSI to differentiate inflammatory from fibrotic disease has been an area of intense interest by our group and others. [25] [26] [27] Indeed, certain modalities such as magnetization transfer MRI 28 and ultrasound 29 show promise, but have not gained widespread use beyond certain centers. The commonly held concept that the lack of inflammatory signs on CSI indicates "inactive" or "fibrotic" disease is not accurate. Although CSI signs such as enhancement, mural stratification, and vascular engorgement are sensitive indicators of inflammation, the lack of these findings does not indicate fibrosis. [25] [26] [27] Indeed, fibrosis and inflammation are so closely linked that surgical resection studies have shown that the best predictor of tissue fibrosis is inflammation. The current recommendation is to do what IBD experts have been doing for decades: to use a combination of clinical, laboratory, radiographic, and endoscopic information to make the best informed clinical decision possible, that is until the technology surpasses our clinical acumen. A useful scoring system incorporating a combination of clinical and radiographic variables is hopefully on the horizon. 30 Although our study cannot help the field develop criteria for differentiating tissue inflammation from fibrosis, we can say that a fixed narrowing, regardless of stricture makeup, predisposes us to serious CD complications.
In our study, the radiologists' strict definition of a stricture was predictive of complications, but the minimal lumen diameter was not. This is likely because there is more to the stricture that is important to the development of complications than just a narrow lumen. The relative contribution of inflammation and fibrosis, the presence of small bowel fissures and sinus tracts, relation to other organs, adhesions, and other factors all likely contribute. Molecular factors or the microbiome also likely play a role. Because, in addition to the presence of a stricture, systemic inflammation was also more common in patients with complications than controls, it is possible that the combination of a stricture with systemic inflammation is particularly risky. This point requires further investigation.
There were several limitations to our study, including the retrospective design. The patients were matched based on timing of exams, and key factors could have been missed. Certain data were less reliably extracted from the EMR, including the indications for which the CSI scans were ordered, the circumstances of IBD surgery (elective versus emergent), or the total duration of CD therapy, particularly steroids. Among other limitations, we did not include data on colonoscopy exams or endoscopic therapeutic procedures (e.g., for strictures).
In conclusion, the presence of a fixed stricture on CSI is predictive of future serious CD complications. In the presence of upstream dilatation, it represents a 3.4 times greater odds for development of a perforation, abscess, obstruction, or fistula, which increases to 15.6 times when there is radiological evidence of inflammation. CSI-derived information should be incorporated into the clinical decision making process alerting the clinician to possible future complications. Risk factor analysis should help clinicians and patients make more informed decisions about medical, surgical, and endoscopic therapies.
